The Safety of High-Dose Intranasal Fentanyl in the Pediatric Emergency Department.
Journal
Pediatric emergency care
ISSN: 1535-1815
Titre abrégé: Pediatr Emerg Care
Pays: United States
ID NLM: 8507560
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
entrez:
1
2
2022
pubmed:
2
2
2022
medline:
3
2
2022
Statut:
ppublish
Résumé
This study aimed to determine if the use of intranasal (IN) fentanyl in the pediatric emergency department of 2 to 5 μg/kg at doses greater than 100 μg is associated with adverse events in pediatric patients. We performed a retrospective chart review of patients receiving IN fentanyl at an urban, tertiary care emergency department in Memphis, TN, from January 1, 2011, to December 31, 2017. All adverse events documented through the hospital's voluntary safety reporting system involving IN fentanyl were reviewed to determine patient outcomes. A total of 3205 patients received greater than 100 μg of IN fentanyl during the study period from 2011 to 2017. The average (SD) patient age was 13.7 (2.65) years, ranging from 5 to 18 years. The mean (SD) initial dose was 162 (30) μg ranging from 102 to 265 μg (2 doses were given greater than 200 μg in the study period). Initial average (SD) dose for weight was 2.62 (0.5) μg/kg. A total of 13 adverse events were documented, with only 3 occurring at doses greater than 100 μg. No patients required the reversal agent naloxone or invasive respiratory support. To our knowledge, this is the first study using doses greater than 100 μg of IN fentanyl in a pediatric population. Our results indicate that fentanyl can be safely administered at doses of greater than 100 μg without any clinically significant adverse outcomes observed for 7 years of use. It is our hope that this information will increase utilization of IN fentanyl for treatment of acute pain in emergency departments and in the prehospital setting.
Identifiants
pubmed: 35100749
doi: 10.1097/PEC.0000000000002627
pii: 00006565-202202000-00013
doi:
Substances chimiques
Analgesics, Opioid
0
Fentanyl
UF599785JZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e447-e450Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: The authors have no conflict of interest.
Références
Drendel AL, Kelly BT, Ali S. Pain assessment for children: overcoming challenges and optimizing care. Pediatr Emerg Care . 2011;27:773–781.
Ali S, Chambers A, Johnson DW. Reported practice variation in pediatric pain management: a survey of Canadian pediatric emergency physicians. CJEM . 2014;16:352–360.
Bailey AM, Baum RA, Horn K, et al. Review of intranasally administered medications for use in the emergency department. Am J Emerg Med . 2017;53:38–48.
Foster D, Upton R, Christrup L, et al. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother . 2008;42:1380–1387.
Lim CB, Paech MJ, Sunderland VB, et al. Pharmacokinetics of nasal fentanyl. J Pharm Pract Res . 2003;33:59–63.
Borland M, Jacobs I, King B, et al. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med . 2007;49:335–340.
Murphy A, O'Sullivan R, Wakai A, et al. Intranasal fentanyl for the management of acute pain in children. Cochrane Database Syst Rev . 2014;2014:CD009942.
MacLaren J, Kain ZN. Research to practice in pediatric pain: what are we missing? Pediatrics . 2008;122:443–444.
Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics . 2010;126:532–537.
Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emerg Med (Fremantle) . 2002;14:275–280.
Graudins A, Meek R, Egerton-Warburton D, et al. The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. Ann Emerg Med . 2015;65:248–254.e1.
Rech MA, Barbas B, Chaney W, et al. When to pick the nose: out-of-hospital and emergency department intranasal administration of medications. Ann Emerg Med . 2017;70:203–211.
Teleflex. Using the LMA® MAD Nasal™ intranasal mucosal atomization device. 2013. Available at: http://www.teleflex.com/en/usa/productAreas/ems/documents/AN_ATM_MAD-Nasal-Usage_Guide_AI_2012-1528.pdf . Accessed January 29, 2020.
Dale O, Hjortkjaer R, Kharasch E. Nasal administration of opioids for pain management in adults. Anaesthesiol Scand . 2002;46:759–770.
Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for? J Pharm Sci . 2009;12:288–311.
Veldhorst-Janssen NML, Fiddelers AAA, van der Kuy PHM, et al. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally. Clin Ther . 2009;31:2954–2987.
Tsze DS, Ieni M, Fenster DB, et al. Optimal volume of administration of intranasal midazolam in children: a randomized clinical trial. Ann Emerg Med . 2017;69:600–609.
Borland M, Milsom S, Esson A. Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial. Emerg Med Australas . 2011;23:202–208.
Ryan PM, Kienstra AJ, Cosgrove P, et al. Safety and effectiveness of intranasal midazolam and fentanyl used in combination in the pediatric emergency department. Am J Emerg Med . 2019;37:237–240.
Coté CJ, Wilson S. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics . 2019;143:2019–1000.